Home > Back to Publisher > Report Information

BioWorld BioPartnering Report 2009: Strategies & Paradigms of the Deal

Bioworld Online/AHC Media
August 1, 2009
250 Pages - SKU: CCAQ2614442

Abstract Table of Contents Related Reports

The "deal" continues to be the trend-setting dynamic in the biotechnology and pharmaceutical markets. Success in the industry has become increasingly impacted by the companies' capacity to engage in partnering transactions, and this new report shows you how to do it.

The BioWorld BioPartnering Report 2009, from the editors of BioWorld Today, provides profound insight, examples and strategies for biotech and pharma companies to identify appropriate partners, negotiate transactions and navigate the aggressive environment in which missteps and hesitation can easily result in lost opportunity.

Compared to 2007, partnering is not only still on a roll, but has shifted into overdrive as it maintains a 10-year run of aggressive activity. Every company in the industry must now understand the elements of successful biopartnering, as pharma is desperately seeking drugs, biotech pursues funding and infrastructure support and VCs remain fiscally cautious.

With the BioWorld BioPartnering Report 2009, you will be able to:

Analyze real-life case studies illustrating the do's and don'ts of successful partnering.
Gain insight from firsthand interviews with seasoned veterans of the partnering process.
Learn tips on how to research and approach potential partners.
Benefit from a special "Keys to Success" section for future reference.
Acquire proven strategies and techniques on the partnering process.
The BioWorld BioPartnering Report 2009 give you tools to make identifying potential partners more simplified: Trends on patent expirations, revenue projections, drug approvals, current collaborations, and deal valuations are provided, as well as a unique "Partnering Profiles" section containing dossiers on pharma and big biotech companies that are aggressively seeking out partners. Details in these profiles include:

The company's partnering strategy
Partnering contacts (licensing and business development)
Scientific and technological areas of interest
Recent partnering collaborations
Company's internal partnering process
The BioWorld BioPartnering Report 2009 gives both parties biotech and pharma companies their best chance at a smooth and successful collaboration from start to finish! Gain the understanding you need to prepare for the events that will significantly affect your company throughout your partnering process.

Introduction and Analysis
Trends: Depressing First Half of 2008 in Worldwide Public Markets; Drug/Device Combos Could Salvage Dropped Compounds; A Match Made in Heaven; R&D Productivity Via Partnering; Drug and Medical Device Deals: A Different Type of Partnership; As Big Pharma Model Falters, Biotech Rides to the Rescue; Deals to M&As: The Culture of False-Flagging, Shape-Shifting
Notable Deals: Autoimmune and Inflammation Deals; Immunomedics Inks Potential $620M Deal with Nycomed; ARYx Seeking New Partner for GI Program after P&G Bails Out; UCB Licenses Keppra, Cimzia Rights in Japan; Alizyme, Norgine Team Up in $67M Marketing Deal; Bionomics Signs Merck Serono in MS, Autoimmune Partnership; TransPharma Gets $35M in Osteo Deal with Lilly; QLT Sells Acne Gel Product Aczone for $150M to Allergan; Start-up TFT Adds NF-Kappa B Decoy Program from Anesiva; Early Stage Antibody Nets EUSA $44M from GSK; Scil, Pfizer Enter $250M Deal for Preclinical Osteo Drug; Catalyst Partners with Centocor for Engineered Protease Drugs; Galapagos Inks $395M Deal with Lilly for Osteo Drugs; Alba Inks Ex-U.S./Japan Deal with Shire for Celiac Drug; Excaliard Snags $15.5M and Isis Fibrosis Drugs; Galapagos and Janssen in RA Partnership; Axcan, Cellerix Deal for Adult Stem Cell Therapy; Radius Grants Novartis Option to BA058 in Potential $500M Deal; Microbia, Forest Collaborate: Up to $330M for IBS Candidate; LigoCyte, Biogen Partner for Work on Inflammatory Diseases; Merck, KineMed Collaborate on Atherosclerosis in RCT Deal; Micromet, Nycomed Enter GM-CSF Deal
Cancer Deals: Seattle Genetics Nets $4M in Deal with Daiichi Sankyo; Exelixis, GSK Wrap Up Six-Year Discovery, Development Deal; ThromboGenics, BioInvent in $775M Roche Oncology Deal; Astex Strikes $500M Deal for its Fibroblast Receptor; ImaRx Shares Spike on Sale of Urokinase to Microbix; CuraGen Sells Cancer Drug to TopoTarget for $45M; Avant, Pfizer Sign $50M Deal for GBM Cancer Vaccine; Amgen Gaining Rights to CCR4 Antibody in $520M Kyowa Deal; Dyax Signs Sanofi to Antibody Deal Potentially Worth $500M; Amgen Unloads 13 Molecules in $1B-plus Deal with Takeda; Alfacell Deals U.S. Rights for Onconase to Strativa; ImmunoGen Entering TAP Cancer Deal with Centocor; Aegera Adds Millions to Coffers in Year-End Deal; Nektar and Baxter Enter Second Hemophilia Agreement; Idera Signs $421M Deal for TLR9 Cancer Agonists; Antibody Deal with GSK Netting OncoMed $1.4B; Merck Serono Takes Japanese Option to R763 from Rigel; Infinity Regains Hedgehog Pathway Inhibitor Program; Synta, GSK Partner for Melanoma Drug in Deal Worth up to $1B; OSI, AVEO Targeting EMT in Cancer Research Collaboration; AVEO Growing Antibody Pipeline; Celgene Paying Array $40M Up Front for Drug Discovery; Pharmion, MethylGene Team for $100M Cancer Partnership; Cell Therapeutics Buys Zevalin in Anticancer Deal Worth $30M; Ariad and Merck Enter Deal on mTOR Inhibitor; Genentech, Abbott Partner to Develop Oncology Drugs; Novacea, Schering-Plough Enter Potential $440M Deal
Cardiovascular and Anemia Deals: Addrenex Signs Second Sciele Deal; KAI, BMS Join Forces in $227M Heart Drug Deal; Wyeth Cancels Hedgehog Collaboration with Curis; Amira Inks $425M FLAP Inhibitor Deal with GSK; PDL Divestiture Continues in $170M Deal with EKR; Inspiration Teams with Celtic in $35M Hemophilia Deal; Isis Pockets $325M Up Front in $1.9B Deal with Genzyme; ThromboGenics: Another Deal for Staphylokinase Heart Drug; Keryx, Japan Tobacco Deal: Possible $100M for Zerenex; BioLineRx Gets BL-4040 Rights; Delves Into Acute Kidney Injury; Isis, BMS Enter Deal on Early Stage Cholesterol Drug
Central Nervous System Deals: Actelion, GSK Ink $3.2B Deal with Almorexant as Centerpiece; Proximagen Stands to Get $232M in Deal for Parkinson’s Drug; Myriad Gets $100M Upfront in European Deal for Flurizan; Spectrum Sale of Profit Shares of Migraine Drug Nets $20M; Astellas, CoMentis in $760M Deal for Alzheimer’s Treatment; $135M Deal Saves Shire Two Years Toward CNS Drug; Vernalis Takes $29M for Now, Giving Up Migraine Revenues; Antisense Licenses MS Drug to Teva for $2M Up Front; Rights to Schizophrenia Drug Worth up to $702M for Addex; Sepracor in $175M Deal with Bial for Epilepsy Drug; BioMS Signs $497M Deal with Lilly for SPMS Drug; Addex Inks $170M Merck Deal for CNS Drug Development; Biogen, Neurimmune Entering Alzheimer’s Deal: Up to $360M
Diabetes and Obesity Deals: Depomed Gets $12M Up Front in Diabetes Deal with Santarus; Diabetes Deal Brings Emisphere Up to $87M from Novo Nordisk; Transition Could Get $130M in Diabetes Deal with Lilly; Alkermes Left at the Altar as Lilly Kills AIR Program; Teva Amends Andromeda Deal for Phase III Diabetes Drug; Smoke Clears; Pfizer Paying Nektar $135M in Exubera Deal; Tolerx, GSK Partner on $760M Diabetes/Psoriasis Product; Hard-Pressed Pfizer Dropping Exubera; Nektar Shares Slump; MacroGenics, Lilly Ink $1B Deal for Diabetes Drug Teplizumab; Vitae, BI Combine Metabolic Programs in $336M Deal; XenoPort Partners Early Stage Candidate in $147M Deal; MedImmune, Crucell in Antibody Deal of up to $40M; Pharmacopeia Adds SARM Program in BMS Deal; Gene Logic Sheds Genomics Assets; Isis Gets $45M Up Front in Deal with Ortho on Diabetes Drugs
HCV and HIV/AIDS Deals: Symphogen, Genentech Sign Antibodies Deal Worth $330M; Vertex Sells Royalty Rights to HIV Inhibitors for $160 Million; Medivir, Tibotec Expand HCV Work in Potential $430M Deal; Presidio Gains Early Hepatitis C Program from XTL in $108M Deal; Tacere Signs Oncolys as Asian Partner in $60M HCV Agreement; ProMetic Partners with Kedrion on Plasma-Derived Proteins; Tacere’s shRNA Drug for HCV Subject of $145M Pfizer Deal; Crucell Signs Sanofi Pasteur in $113M Rabies Antibodies Deal; Santaris Gets $700M from GSK in Antiviral LNA-Based Drug Pact; Gilead Adds to Fibrotic Disease Pipeline in $202M Deal with LGLS; Nektar Keeps Promotion Rights in $175M Deal on Amikacin Drug; Tobira Ramps up HIV Pipeline with Two Candidates and $31M
Pain Deals: Amgen Sells Pain Molecule to J&J in $385M Deal; Encore, PainReform in Pain Collaboration; Adolor Inks $265M Deal with Pfizer for Opioid; Alexza Licenses Inhaled Fentanyl Product To Endo; $10M Up Front; India’s Glenmark in $350M Deal with Lilly for Pain Compound; Cephalon Acquiring Approved Muscle Relaxant for $100M; Icagen-Pfizer Deal: Potential $1B-Plus for Pain Therapies; Targacept NNR Platform Lands in Billion-Dollar GSK Alliance; Hydra Lands Deal with Pfizer on Pain Drugs
RNAi Deals: Alnylam Signs Japanese Partner for RNAi-Based RSV Program; Alnylam Signs Potential $1B RNAi Agreement with Takeda; Regulus, GSK Ink $600M Deal for Drugs Targeting MicroRNA; Source MDx Signs Pfizer to RNA-Based Biomarker Deal; Alnylam, Merck Parting Ways; RNAi Stalemate Over at Last; Alnylam, Medtronic Expand Deal with RNAi Drug-Device Combos; Alnylam Captures Potential $1B Roche Licensing Deal
Vaccine and Bacterial Disease Deals: Mpex, GSK in Antibiotics Deal Using Efflux Pump Inhibitors; Emergent Adding FluBlok to Vaccine Arsenal in PSC Buy; VaxGen Sells Anthrax Vaccine to Emergent for Potential $10M; Takeda Paying $50M Up Front for GVAX in Prostate Cancer; PharmAthene Buys Vaccines from Avecia in $40M Deal; Receptor Logic Finds Partner to Develop T-Cell Mimics; Novexel in Deal for Beta Lactamase Inhibitor; AmVac Signs Two Deals to Boost Vaccine Program; Maxygen Licenses Antigens to Sanofi Group for $24.5M; Acambis Partners West Nile Vaccine in $80M Sanofi Deal; Merck Paying $31M Up Front in Dynavax HBV Vaccine Deal; Emergent Snags $448M Deal for Anthrax Vaccine; Intercell, Novartis Enter Pact
Mergers and Acquisitions: Ahead of OncoGenex Merger, Sonus Adds Caspase Program; Clinical Data Boosts Pipeline with Adenosine Buyout; BMS After ImClone; Offers $60 per Share for Erbitux Partner; Roche on a Roll; Getting Arius for $190M; $125M Deal Sends Mirus Bio Into the Roche RNAi Camp; Synergy Gets $3M Offering; Callisto Gets Reverse Merger; Roche $43.7B Genentech Offer Makes Headlines; Integration a Key Aspect of Roche/Genentech Proposal; MacroGenics Boosts Anticancer Pipeline with Raven Acquisition; Novartis Buying Speedel With Help of Top Brass; ViroPharma to Acquire Lev Paying $443M Up Front; Access Expands Pipeline with MacroChem Merger; SGX Shares Soar on Merger Giving Lilly Technology Boost; Lilly Gets Discovery Partner SGX in a Deal Worth $64M; VGX Plans a Strategic Reverse Merger with Inovio; Shire Paying Jerini $519M for HAE Compound Firazyr; BI Looking to Buy Actimis for $515M if Asthma Drug Works; CytRx Rescues Innovive in $25M Buyout, Adds Four Cancer Drugs; Invitrogen, Applied Biosystems Join Forces in $6.7B Merger; Tercica Goes to Ipsen in $663M Transaction; $400M Deal for Protez Gives Novartis Superbug Candidate; Arno Gets $18M Plus Market Access in Reverse Merger; Gen-Probe Makes Counterbid for Diagnostics Firm Innogenetics; Kosan’s Cancer Pipeline Attracts $5.50 Per Share BMS Buyout Bid; Struggling Sonus Building Value, Pipeline via OncoGenex Merger; Daiichi Sankyo to Purchase German Biotech for $235M; Bone Regeneration Product Brings in $85M for Osiris; Antisoma Boosts Pipeline with $52M Xanthus Buy; Cash-Strapped Iomai Jumps on $189M Buyout Bid by Intercell; Critical Therapeutics Investors Balk Over Cornerstone Merger; Sepracor Forging Ahead in ’08, on Oryx Buy; GSK Grabbing Sirtuin Platform with $720M Sirtris Acquisition; Roche Buying Privately Held Piramed for $160M Up Front; Takeda Getting Millennium, Velcade in $8.8B Cash Deal; With No Partner and Little Cash, CeNeS Goes to Paion for $21.9M; Abraxis Buys Two Companies, Gets Cyclodextrin Platform; Tekmira and Provita Merge to Form RNAi Powerhouse; AVI Buying Ercole, Combining RNA Splicing Work, Portfolio; EUSA Gains Commercial Status with $22M Cytogen Purchase; Pfizer Acquires Serenex for Undisclosed Amount; CollaGenex Being Acquired by Galderma for $420M Cash; Cypress Buys into Personalized Medicine with $75M Proprius Deal; Pfizer $195M Deal for Encysive Called a ‘Good Deal’ for Both; Apex Bioventures Acquiring Dynogen in $135M Stock Deal; Isis Nets $20M from Abbott for Share of Ibis Subsidiary; Teva Buying HGS Spinout CoGenesys for $400M Cash; In $57M Buyout, Invitrogen Adds Hepatocyte-Based Products; Alkermes Gets $166M Boost from GSK’s Reliant Buyout; CovX’s Peptide-Antibody Bid Attracts Acquisition by Pfizer; Biogen Fails to Attract Bids; Firm to Operate Independently; Eisai Gaining Cancer Portfolio in $3.9B MGI Acquisition
ImmunoVaccine Nabs Immunotope: Precision Therapeutics’ IPO Set Aside; Merger Planned; Amarin Obtains MRNA Platform, Phase II Drug Via Acquisition; Astellas Buying into Cancer; $387M Up Front for Agensys; $1.65B Deal for Reliant Boosts GSK Cardio Line; Pfizer Boosts Vaccine Pipeline with $164M Deal for Coley; Celgene’s $2.9B for Pharmion Nets Hematology, Cancer Lines; AstraZeneca Folds Cambridge Antibody into MedImmune; Avant, Celldex Plan Merger; New Company Worth $115M; Cubist Gets Option to Acquire Illumigen; Funds HCV Drug; Aspreva Ends Speculation with $915M Acquisition; Orexo Acquires a Pipeline in $133M Deal for Biolipox; Dara, Point Therapeutics Join in Reverse-Merger Rescue; QLT Buys Eye Device Firm for $42M Plus Milestones; Align Acquisition Pads Cyclacel’s Resource Base; Haptogen Acquisition Brings Shark Therapies to Wyeth; PerkinElmer to Acquire ViaCell But Will Divest Cell Therapies; Adnexus Nixes IPO Route, Opts for $430M BMS Exit; Virxsys Acquires Intronn, Gets RNA Payloads for Gene Therapy; Evotec Plans Acquisition of Renovis in $152M Stock Deal; Nabi’s ‘Turnaround’ Continues, Sells Biologics Unit for $185M; Entelos Adds Disease Models with the Acquisition of Iconix; Upstream Completes Acquisition of Firm Focused on Parasites; Cash-Poor IsoTis Acquired by Integra in $51M Deal; Aegera Acquires LymphoSign, Completes Series C; Neuren Acquires Hamilton, Gets Phase II CNS Drug; Cell Therapeutics Gets Phase II Cancer Drug in SMi Acquisition; Merck Paying $350M in Stock for Acquisition of NovaCardia; Sanofi Building Vaccine Pipeline with $549M Buyout of Acambis; BMS After ImClone; Offers $60 per Share for Erbitux Partner
Keys to Success: First Things First: Finding a Partner; Are Biotechs Built to Prosper or Are They Built to be Sold?; What Does Big Pharma Want?; Tips When Thinking About Partnerships; Reasons to Partner; Tips for Negotiating the Deal; Planning for Failure; Avoiding Failure: Alliance Management; Alliance Management the Eli Lilly Way; After the Deal: Preparing for a Commercial Launch; Challenges in Biopartnering; Model Changing, But Alliances with Nonprofits Still Valuable
Industry Interviews: An Interview with Greg Wiederrecht, Vice President and Head of the External Scientific Affairs Department of the Merck Research Laboratories, Merck & Co. Inc.; An Interview with Warwick S. Bedwell, Vice President, Global Head of Business Development, Pharma Partnering, Roche; An Interview with Robert L. Little, Vice President and Chief Commercial Officer, Halozyme Therapeutics Inc.; An Interview with Kevin Giese, President and CEO, BioMS Medical Corp.; An Interview with Safi R. Bahcall, President and CEO, Synta Pharmaceuticals Corp.; An Interview with Todd Davis and Gregory Brown, co-founders and Managing Directors of Cowen Healthcare Royalty Partners
Partnering with Big Pharma and Big Biotech: Smart Partnerships: Filling Gap for Pharma, Financing Biotech; Partnering Tables Turn as Big Pharma Pitches Biotech; Abbott Laboratories; Alcon Inc.; Amgen Inc.; AstraZeneca plc; Bayer Healthcare Pharmaceutical; Biogen Idec Inc.; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Co.; Eisai Inc.; Eli Lilly and Co.; EMD Serono Inc.; Genentech Inc.; Genzyme Corp.; GlaxoSmithKline plc; H. Lundbeck A/S; Jazz Pharmaceuticals Inc.; Johnson & Johnson; Merck & Co. Inc.; Novartis AG; Novo Nordisk A/S; Nycomed A/S; Organon International; P&G Pharmaceutical Inc.; Pfizer Inc.; Roche; Sanofi Pasteur; Schering-Plough Corp.; Shire plc; Solvay Pharmaceutical Inc.; Takeda Pharmaceutical Co. Ltd.; TAP Pharmaceutical Products Inc.; Wyeth
Index
LIST OF TABLES: Introduction and Analysis; Trends; Keys to Success

BioWorld BioPartnering Report 2009: Strategies & Paradigms of the Deal

Share this report

Other tasks

Research Assistance

Related Markets

Biopharmaceuticals Reports

Free Alert Me service